Curriculum Vitae
`
`NAME:
`
`Thomas Charles Dowling
`
` Ferris State University
`WORK
`ADDRESS College of Pharmacy
` 25 Michigan Ave NE, Suite 7000
` Grand Rapids, MI, 49503
` Phone/Fax: 616-643-1139
` Email: ThomasDowling@ferris.edu
`
`EDUCATION
`
`Sept. 1994- July 1999
`
`Doctor of Philosophy – Pharmaceutical Sciences
`School of Pharmacy, Department of Pharmaceutical Sciences,
`University of Pittsburgh, Pittsburgh, PA
`
`July 1993-July 1994
`
`Pharmacy Practice Residency, University of Maryland Medical System,
`Baltimore, MD
`
`May 1988-May 1993
`
`Doctor of Pharmacy (High Distinction); May 1993
`Associate of Arts and Sciences (Distinction); May 1990
`Ferris State University College of Pharmacy, Big Rapids, Ml
`
`May 1987- May 1988
`
`Alpena Community College, Alpena, Ml
`
`EMPLOYMENT
`
`Nov 2014 – Present
`
`Assistant Dean, Research Professional Development (2014 - )
`Department Head – Pharmacy Practice (2014-2015)
`Professor (Tenured)
`
`Director, Office of Research and Sponsored Programs (2014 - )
`
`Institutional Official for IRB and IBC (2021 - )
`
`Ferris State University, College of Pharmacy
`Grand Rapids, MI
`
`July 2014 – Oct 2014
`
`Professor (tenured)
`Vice Chair for Research and Scholarship (2008 - 2014)
`Department of Pharmacy Practice and Science
`University of Maryland School of Pharmacy, Baltimore MD
`
`July 2005 – June 2014
`
`Associate Professor (tenured)
`Vice Chair for Research and Scholarship (2008 - 2014)
`Department of Pharmacy Practice and Science
`University of Maryland School of Pharmacy, Baltimore MD
`APOTEX EXHIBIT 1047
`Apotex v. Alkermes
`IPR2025-00514
`
`1
`
`

`

`Aug. 1999 – Jul. 2005
`
`Assistant Professor
`Department of Pharmacy Practice and Science
`University of Maryland School of Pharmacy, Baltimore MD
`
`Nov. 1994- June 1997
`
`Pharmacist, Veteran's Administration Hospital, Pittsburgh PA
`
`July - Sept. 1994
`
`Clinical Pharmacist (Nephrology), University of Maryland Medical System,
`Baltimore MD
`
`SCHOLARLY ACTIVITY
`
`Publications (peer-reviewed journals):
`
`1. Morris JG, Shay DK, Hebden JN, McCarter RJ, Perdue BE, Jarvis W. Johnson JA, Dowling
`TC, Polish LB, Schwalbe RS. Enterococci resistant to multiple agents, including vancomycin:
`establishment of endemicity in a University Medical Center. Ann Intern Med
`1995;123:250-259.
`
`2. Dowling TC, Frye RF, Zemaitis M. Simultaneous determination of p-aminohippuric acid, acetyl-p-
`aminohippuric acid and iothalamate in human plasma and urine by high-performance liquid
`chromatography. J Chromatogr B 1998;716:305-313.
`
`3. Dowling TC, Frye RF. Determination of famotidine in human plasma and urine by HPLC. J
`Chromatogr B 1999; 732:239-243.
`
`4. Dowling TC, Frye RF, Fraley DS, Matzke GR. Comparison of iothalamate clearance methods for
`measuring GFR. Pharmacotherapy 1999;19(8):943-950.
`
`5. Dowling TC, Frye RF, Fraley DS, Matzke GR. Characterization of tubular functional capacity in
`man using PAH and famotidine. Kidney Int 2001;59:295-303.
`
`6. Raje S, Dowling TC, Eddington ND. Determination of the benztropine analog AHN-1055, a
`dopamine uptake inhibitor, in rat plasma and brain by HPLC with UV detection. J Chromatogr B
`2002;768:305-313.
`
`7. Karyekar CS, Eddington ND, Dowling TC. Effect of St. John’s Wort on CYP1A2 in LS180 cells. J
`Postgrad Med 2002;48:100-104.
`
`8. Karyekar CS, Fasano A, Raje S, Lu R, Dowling TC, Eddington ND. Zonula occludens toxin
`increases the permeability of molecular weight markers and chemotherapeutic agents across the
`bovine brain microvessel endothelial cells. J Pharm Sci 2003 Feb;92(2):414-23.
`
`9. Karyekar CS, Garimella T, Eddington ND, Dowling TC. Evaluation of the P-glycoprotein-
`mediated interactions between cimetidine, PSC833 and itraconazole in MDR1-MDCK cells.
`Pharmacotherapy 2003 Apr;23(4):436-42.
`
`10. Dowling TC, Briglia A, Fink J, Hanes D, Light P, Stackewicz L, Karyekar CS, Eddington N, Weir
`M, Henrich WL. Characterization of hepatic CYP3A activity in ESRD patients. Clin Pharmacol
`Ther 2003 May;73(5):427-34.
`
`2
`
`

`

`11. Iqbal T, Karyekar CS, Kinjo M, Ngan G, Dowling TC. Validation of a simplified method for
`determination of cimetidine in human plasma and urine by HPLC with ultraviolet detection. J
`Chromatogr B 2004;799(2):337-341.
`
`12. Karyekar CS, Eddington ND, Briglia AE, Gubbins PO, Dowling TC. Renal interaction between
`itraconazole and cimetidine. J Clin Pharmacol 2004;44:919-927.
`
`13. Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, Greenberg N, Thattassery
`E, Fisher ML, Rao K, Gottlieb SS. Nesiritide Does Not Improve Renal Function in Patients with
`Chronic Heart Failure and Worsening Serum Creatinine. Circulation 2004 Sep 21;110(12):1620-
`5.
`
`14. Dowling TC, Arjomand M, Lin ET, Allen LV, McPherson ML. Systemic absorption of topically
`applied single dose ketoprofen 20% in pluronic lecithin organogel (PLO). Am J Health Syst
`Pharm 2004 Dec 1;61(23):2541-4.
`
`15. Iqbal T, Kinjo MT, Dowling TC. Determination of Rhodamine-123 in cell lysate buffer using
`HPLC with visible UV detection. J Chromatogr B 2005 Jan 25;814(2):259-262.
`
`16. Dowling TC, Edelman R, Chavaillaz P, Young D, O’Brien A, Khazaeli D, Roberson C, Tacket
`CO. Phase I safety and pharmacokinetic study of chimeric murine-human monoclonal antibody
`cαStx2 in healthy adults. Antimicrob Agents Chemother 2005;49:1808-1812.
`
`17. Jones JM, Johnson JJ, Vizcaino D, Park JJ, Hand BD, Ferrell RE, Weir MR, Dowling T,
`Obisesan TO, Brown MD. Renin-Angiotensin System Genes and Exercise Training-Induced
`Changes in Sodium Excretion in African American Hypertensives. Ethnic Dis 2006;16(3):666-
`674.
`
`18. Jones J, Park JJ, Dowling T, Phares D, Park JY, Brown MD. Role of potassium excretion and
`percent body fat on ethnic differences in plasma aldosterone levels. Ethnic Dis 2006;16(3 suppl
`4):S4-S10.
`
`19. Jones-Burton C, Vessal G, Dowling TC, Brown J, Fink JC. Urinary Cotinine as an Objective
`Measure of Cigarette Smoking in Chronic Kidney Disease. Nephrol Dial Transplant 2007
`Jul;22(7):1950-4.
`
`20. Jones JM, Dowling TC, Park JJ, Roth S, Phares DA, Park JY, Brown MD. Differential Aerobic
`Exercise-Induced Changes in Plasma Aldosterone between African Americans and Whites. Exp
`Physiol 2007 Sep;92(5):871-9.
`
`21. Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic
`benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health
`Syst Pharm 2007 Jul 1;64(13 Suppl 8):S3-7.
`
`22. Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S. The effect of KW-3902, an
`adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients
`with heart failure and renal impairment. J Card Fail 2007 Oct;13(8):609-17.
`
`23. Rogers HL, Marshall J, Brock J, Dowling TC, Feller E, Robinson S, Gottlieb SS. A Randomized,
`Controlled Trial of the Renal Effects of Ultrafiltration as Compared to Furosemide. J Card Fail
`2008 Feb;14(1):1-5.
`
`3
`
`

`

`24. Howell CD, Dowling TC, Paul M, et al. Peginterferon pharmacokinetics in African American and
`Caucasian American in patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol
`Hepatol 2008 May;6(5):575-83.
`
`25. Sturgeon KM, Fenty-Stewart NM, Diaz KM, Brinkley TE, Dowling TC, Brown MD. The
`Relationship of Oxidative Stress and Cholesterol with Dipping Status Before and After Aerobic
`Exercise Training. Blood Pressure 2009 Jun 18:1-9.
`
`26. Bivins A, Hou K, Ayesu N, Ellsworth B, Montenegro S, Tu X, Boyle C, Dowling T, Shaya FT.
`Clinical evaluation of natalizumab for formulary consideration. Expert Opin Biol Ther 2010
`Aug;10(8):1279-87.
`
`27. Dowling TC, Murphy JE, Matzke GR, Burkhart GJ. Evaluation of renal drug dosing: Prescribing
`information and clinical pharmacist approaches. Pharmacotherapy 2010;30(8):776–786.
`
`28. Klein-Schwartz W, Doyon S, Dowling TC. Drug Adsorption Efficacy and Palatability of a Novel
`Charcoal Cookie Formulation. Pharmacotherapy 2010; 30(9):888–894.
`
`29. Denetclaw T, Oshima N, Dowling TC. Dofetilide Dose Calculation Errors in Elderly Associated
`with Use of the MDRD eGFR Equation. Ann Pharmacother 2011;45(7-8):e44.
`
`30. Nyman HA, Dowling TC, Hudson JQ, St. Peter WL, Joy MS, Nolin TD. Use of the Cockcroft-
`Gault versus the MDRD Study Equation to Dose Medications: An Opinion of the Nephrology
`Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy
`2011 Nov;31(11):1130-44.
`
`31. Jin R, Fossler MJ, McHutchison JG, Howell CD, Dowling TC. Population Pharmacokinetics and
`Pharmacodynamics of Ribavirin in Patients with Chronic Hepatitis C Genotype 1 Infection. AAPS
`J 2012;14(3):571-80.
`
`32. Shao C, Dowling TC, Haidar S, Yu LX, Polli JE, Kane MA. Quantification of acyclovir in human
`plasma by ultraperformance liquid chromatography – heated electrospray ionization – tandem
`mass spectrometry for bioequivalence evaluation. J Anal Bioanal Techniques 2012;3(4):1-6.
`doi:10.4172/2155-9872.1000139
`
`33. Jin R, Cai L, Tan M, McHutchison JG, Dowling TC, Howell CD. Optimum ribavirin exposure
`overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C
`genotype 1. Am J Gastroenterol 2012 Nov;107(11):1675-83. doi: 10.1038/ajg.2012.306.
`
`34. Dowling TC, Rodriguez de Bittner M, Perez Z, Briglia A, Peralta L. Evaluation of Drug
`Metabolism in Hispanic Americans with Type 2 Diabetes. Diab Res Clin Metab 2012; Dec
`21:doi:10.7243/2050-0866-1-22.
`
`35. Congdon HB, Dowling TC, Cheng I, Truong HA. Impact of Medication Therapy Management
`(MTM) Visit Frequency on Diabetes Control in a Health Resources and Services Administration
`Patient Safety and Clinical Pharmacy Services Collaborative. Ann Pharmacother 2013
`May;47(5):665-70.
`
`36. Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular Filtration Rate Equations Overestimate
`Creatinine Clearance in Older Individuals Enrolled in the Baltimore Longitudinal Study on Aging:
`Impact on Renal Drug Dosing. Pharmacotherapy 2013;33(9):912-21. doi: 10.1002/phar.1282.
`
`4
`
`

`

`
`
`
`
`37. Sheth N, Dowling TC, Congdon H. Evaluation of synchronous versus live instructional delivery
`methods on student academic outcomes and perceptions at a multi-campus school. Curr Pharm
`Teach Learn 2013;5(5):381-386. doi: 10.1016/j.cptl.2013.03.005
`
`38. Chang Y, Burckart GJ, Lesko LJ, Dowling TC. Evaluation of Hepatic Impairment Dosing
`Recommendations in FDA-Approved Product Labels. J Clin Pharmacol 2013 Sep;53(9):962-6.
`DOI: 10.1002/jcph.128.
`
`39. Denetclaw T, Dowling TC, Steinke D. Evaluation of a Divided-Load Intravenous Vancomycin
`Dosing Strategy for Critically Ill Patients. Ann Pharmacother 2013 Dec;47(12):1611-7. doi:
`10.1177/1060028013510395.
`
`40. Volpe DA, Tobin GA, Tavakkoli F, Dowling TC, Light PD, Parker RJ. Effect of uremic serum and
`uremic toxins on drug metabolism in human microsomes. Regul Toxicol Pharmacol 2014;
`68(2):297-303. doi: 10.1016/j.yrtph.2013.10.006.
`
`41. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS. Performance of
`chronic kidney disease epidemiology collaboration (CKD-EPI) creatinine-Cystatin C equation for
`estimating kidney function in cirrhosis. Hepatology 2014;59(4):1532-42. doi: 10.1002/hep.26556.
`
`42. Mindikoglu AL, Dowling TC, Cheong JJ, Christenson RH, Magder LS, Hutson W, Seliger SL,
`Weir MR. A Pilot Study to Evaluate Renal Hemodynamics in Cirrhosis by Simultaneous
`Glomerular Filtration Rate, Renal Plasma Flow, Renal Resistive Indices and Biomarkers
`Measurements. Am J Nephrol 2014; 39 (6), pp. 543-552. doi: 10.1159/000363584
`
`43. Mindikoglu AL, Dowling TC, Magder LS, Christenson RH, Weir MR, Seliger SL, Hutson WR,
`Howell CD. Estimating Glomerular Filtration Rate in Patients with Cirrhosis: Refinement of the
`Chronic Kidney Disease Epidemiology Collaboration Creatinine-Cystatin C Equation. Clin
`Gastroenterol Hepatol. 2015 Jun 29. pii: S1542-3565(15)00845-9. doi:
`10.1016/j.cgh.2015.06.021.
`
`44. Hollis AL, Heil EL, Nicolau DP, Odonkor P, Dowling TC, Thom KA. Validation of a Dosing
`Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. Surg Infect 2015
`Dec;16(6):829-32.
`
`45. Matzke GR, Dowling TC, Marks SA, Murphy JE. Influence of kidney disease on drug disposition:
`An assessment of industry studies submitted to FDA for new chemical entities 1999-2010. J Clin
`Pharmacol. 2015 Aug 4. doi: 10.1002/jcph.604.
`
`46. Mindikoglu AL, Dowling TC, Schaub DJ, Hutson WR, Potosky DR, Christenson RH, Barth RN,
`LaMattina JC, Hanish SI, Weir MR, Raufman JP. Pharmacokinetics and Tolerability of
`Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal
`Dysfunction. Dig Dis Sci 2015;60(11):3491-4. doi: 10.1007/s10620-015-3771-0.
`
`47. Denetclaw TH, Yu MK, Moua M, Dowling TC, Steinke D. Performance of a Divided-Load
`Intravenous Vancomycin Dosing Strategy for Obese Patients. Ann Pharmacother 2015
`Aug;49(8):861-8. doi: 10.1177/1060028015586423
`
`48. Vaithianathan S, Haidar SH, Zhang X, Jiang W, Avon C, Dowling TC, Shao C, Kane M, Hoag
`SW, Flasar MH, Ting TY, Polli JE. Effect of Common Excipients on the Oral Drug Absorption of
`
`
`
`5
`
`

`

`Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. J Pharm Sci.
`2015 Sep 16. doi: 10.1002/jps.24643.
`
`
`
`
`
`49. Martinez, M., Mistry, B., Lukacova, V., Polli, J., Hoag, S., Dowling, T. C., Kona, R., Fahmy, R
`Use of Modeling and Simulation Tools for Understanding the Impact of Formulation on the
`Absorption of a Low Solubility Compound: Ciprofloxacin. AAPS Journal 2016;18(4), 886-897.
`
`50. Martinez MN, Mistry B, Lukacova V, Lentz KA, Polli JE, Hoag SW, Dowling T, Kona R, Fahmy
`RM. Exploring Canine-Human Differences in Product Performance. Part II: Use of Modeling and
`Simulation to Explore the Impact of Formulation on Ciprofloxacin In Vivo Absorption and
`Dissolution in Dogs. AAPS J. 2017; May;19(3):712-726.
`
`51. Medina-Moreno S, Dowling TC, Zapata JC, Le NM, Sausville E, Bryant J, Redfield RR, Heredia
`A. Targeting of CDK9 with indirubin 3’-monoxime safely and durably reduces HIV viremia in
`chronically infected humanized ice. PLoS One 2017; Aug 17;12(8):e0183425.
`
`52. Mindikoglu AL, Opekun AR, Putluri N, Devaraj S, Sheikh-Hamad D, Vierling JM, Goss JA, Rana
`A, Sood GK, Jalal PK, Inker LA, Mohney RP, Tighiouart H, Christenson RH, Dowling TC, Weir
`MR, Seliger SL, Hutson WR, Howell CD, Raufman JP, Magder LS, Coarfa C. Unique
`metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Transl
`Res. 2018 May;195:25-47.
`
`53. Mindikoglu AL, Opekun AR, Mitch WE, Magder LS, Christenson RH, Dowling TC, Weir MR,
`Seliger SL, Howell CD, Raufman JP, Rana A, Goss JA, Khaderi SA, Vierling JM. Cystatin C is a
`gender-neutral GFR marker in patients with cirrhosis. Dig Dis Sci. 2018 Mar;63(3):665-675.
`
`54. Stockton WM, Nguyen T, Zhang L, Dowling TC. Etoposide and etoposide phosphate
`hypersensitivity in children: Incidence, risk factors, and prevention strategies. J Oncol Pharm
`Pract. 2019 Jul 18:1078155219858390. https://doi.org/10.1177/1078155219858390
`
`55. Chen AMH, Sweeney M, Sprague JE, Dowling TC, Durst SW, Eberle MM, Stolte SK, Talbot JN.
`Stimulating and sustaining scholarly activity at teaching-intensive institutions. Currents Pharm
`Teach Learn 2020;13(3):228-237. https://doi.org/10.1016/j.cptl.2020.10.005
`
`56. Schultz CR, Swanson MA, Dowling TC, Bachmann AS. Probenecid increases renal retention
`and antitumor activity of DFMO in neuroblastoma. Cancer Chemother Pharmacol
`2021;88(4):607-617. https://doi.org/10.1007/s00280-021-04309-y
`
`
`57. Cucci MD, Gerlach AT, Mangira C, Murphy CV, Roberts JA, Udy AA, Dowling TC, Mullen CL.
`Performance of different body weights in the Cockcroft-Gault equation in critically ill patients with
`and without augmented renal clearance: A multicenter cohort. Pharmacotherapy
`2023;43(11):1131-1138. https://doi.org/10.1002/phar.2743
`
`58. Dowling TC, Thomas A, Gums J. Survey of direct patient care and payment models among
`pharmacy practice faculty. Journal of the American College of Clinical Pharmacy 2022; 5(5):490-
`495. https://doi.org/10.1002/jac5.1605
`
`59. Bayles CE, Hale DE, Konieczny A, Anderson VD, Richardson CR, Brown KV, Nguyen JT, Hecht
`J, Schwartz N, Kharel MK, Amissah F, Dowling TC, Nybo SE (2023). Upcycling the
`
`
`
`6
`
`

`

`
`
`
`
`anthracyclines: New mechanisms of action, toxicology, and pharmacology. Toxicol Appl
`Pharmacol 2023:459:116362. https://doi.org/10.1016/j.taap.2022.116362.
`
`Publications Other Than Refereed Articles:
`
`Invited Reviews:
`
`1. Dowling TC. Drug metabolism considerations in patients with chronic kidney disease. J
`Pharmacy Practice 2002;15(5):415-423.
`2. Hess HM, Dowling TC, Schwartz MJ. Clinical implications of the differences in dissolution and
`absorption characteristics of oral estrogen therapy agents. Today’s Therapeutic Trends
`2003;21(1):85-96.
`3. Bauer KS, Dowling TC. Update on clinical pharmaceutical sciences programs: University of
`Maryland experience. AAPS Newsmagazine 2004;7(8):14-17.
`4. Dowling TC. Controversies in Renal Function Assessment. In PSAP VI Nephrology, American
`College of Clinical Pharmacy, St. Louis, MO, USA, July 2007.
`5. Dowling TC. Disclosure and the Ethical Conduct of Clinical Research. Am J Health Syst Pharm
`2008 Oct 1;65(19):1851-3.
`6. Dowling TC, Murphy JE, Kalus J, et al. Recommended education for pharmacists as competitive
`clinical scientists: A commentary from the American College of Clinical Pharmacy.
`Pharmacotherapy 2009 Feb;29(2):236-44.
`7. Dowling, T. C. Predicting the risk of kidney failure. Pharmacotherapy Update (Sept. 12, 2016.) In
`Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds), Pharmacotherapy: A
`pathophysiologic approach, 10th edition, McGraw-Hill, New York, NY.
`8. Dowling, T. C., Ding, Q. (2022). Research and Scholarly Methods: Subgroup Analysis. J Am
`College Clin Pharm 2022.
`
`Book Chapters:
`9. Dowling TC, Comstock TJ. Quantification of renal function. In Dipiro JT, Talbert RL, Yee GC,
`Matzke GR, Wells BG, Posey LM (eds), Pharmacotherapy: A pathophysiologic approach, 6th
`edition, McGraw-Hill, New York, NY, 2005.
`10. Haines S, Dowling TC, Harvey D. Pharmacokinetics and pharmacodynamics of warfarin. In
`Evans W, Shentag J, Jusko W (eds), Applied Pharmacokinetics. Principles of Therapeutic Drug
`Monitoring, Applied Therapeutics, Inc., Vancouver, WA, 2005.
`11. Dowling TC, Matzke GR. Dosing Concepts in Renal Dysfunction. In Murphy JE, Clinical
`Pharmacokinetics 3rd, 4th , 5th , 6th Editions, American Society of Health System Pharmacists,
`Bethesda, MD, 2004, 2008, 2011, 2012, 2017.
`12. Dowling TC. Evaluation of Kidney Function. In Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells
`BG, Posey LM (eds), Pharmacotherapy: A pathophysiologic approach, 7th, 8th, 9th, 10th, 11th
`editions, McGraw-Hill, New York, NY, 2008, 2011, 2014, 2017, 2020.
`13. Dowling TC. Basic Biopharmaceutics, Pharmacokinetics and Pharmacodynamics. In Fred LY
`(editor), Manual for Pharmacy Technicians, 4th Edition, American Society of Health System
`Pharmacists, Bethesda, MD, 2011.
`14. Dowling TC. Randomized Clinical Trials. In Principles of Research Design and Drug Literature
`Evaluation . 1st Edition, Aparasu RR, Ed. Jones & Bartlett Learning, Burlington, MA, 2014.
`15. Dowling TC, Smith CL. Acute Kidney Injury. In B. Erstad (Ed.), Critical Care Pharmacotherapy.
`ACCP Publisher. Lanexa, KS. 2016.
`16. Dowling TC. Assessment of Kidney Function (NKF). In J. Hudson & D. Mason (Eds.),
`Nephrology Pharmacotherapy: A Pharmacist's Guide to Advanced Kidney Disease and
`
`
`
`7
`
`

`

`
`
`
`
`Medication Management. Franklin, TN: FreseniusRx. 2016.
`17. Dowling TC. In Beringer PM (ed), Winter’s Basic Clinical Pharmacokinetics, 6th edition, Wolters
`Klewer Health, Philadelphia, PA. 2018
`18. Dowling TC. Chapter 8: Drugs and the Body: Basic Biopharmaceutics, Pharmacokinetics and
`Pharmacodynamics. ASHP Manual for Pharmacy Technicians, 5th Edition, pp. 263-281. ASHP,
`Bethesda, MD. 2019
`19. Nguyen T, Tran T, Dowling TC. Chapter 21. Principles of Drug Therapy in Reduced Kidney
`Function. Kidney Protection: A Practical Guide to Preserving Renal Function in Acute and
`Chronic Disease (1st Edition ed.). New York, NY: Oxford University Press. 2019
`20. Bernknopf AC, Dowling TC. Randomized Controlled Trials (Ch. 4). Principles of Research
`Design and Drug Literature Evaluation, 2nd edition. New York, NY: McGraw-Hill. 2019
`21. Vanloo DA, Dowling TC. Renal Drug Dosing Concepts (Chapter 3). In J. E. Murphy (Ed.),
`Clinical Pharmacokinetics (7th Ed). ASHP, Bethesda, MD. 2022
`22. Smith CL, Dowling TC. Acute Kidney Injury: Prevention and Management. In B. E. (Ed.), Critical
`Care Pharmacotherapy, 2nd edition. ACCP, Lanexa, KS. 2022
`23. Awdishu L, Dowling TC (2023). Evaluation of Kidney Function. In Dipiro JT, Yee GC, Posey LM,
`Haines ST, Nolin TD, Ellingrod V (eds), Pharmacotherapy: A pathophysiologic approach, 12th
`edition, McGraw-Hill, New York, NY, 2023.
`24. Dowling TC. Drug Dosing in Kidney Disease and Dialysis. In Beringer PM (ed), Winter’s Basic
`Clinical Pharmacokinetics, 7th edition, Wolters Klewer Health, Philadelphia, PA. 2024
`
`Monographs, Letters and Published Conference Proceedings:
`25. Cohen HI, Dowling TC, Goodin S. Anemia in cancer and chronic kidney disease: Clinical and
`financial considerations. ASHP Advantage, Bethesda, MD, 2005. (1.5 CEU)
`26. Dowling TC, Matzke GR, Murphy JE. Estimated GFR vs. creatinine clearance for drug dosing.
`Am J Kidney Dis 2009 Nov;54(5):984-5. (Letter)
`27. Howell CD, Jin R, Dowling TC. Reply to: Understanding triphasic HCV decline during treatment
`in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling. J
`Hepatol 2012 Dec 11 (Letter) doi:pii: S0168-8278(12)00923-3. 10.1016/j.jhep.2012.12.004.
`28. Dorshow, R. B., Debreczeny, M. P., Dowling, T. C. Results of the first-in-human clinical trial for
`MB-102, a novel fluorescent tracer agent for real-time measurement of glomerular filtration rate
`(SPIE, vol. 9339, pp. 933906).
`29. Vaithianathan, S., Haidar, S. H., Zhang, X., Jiang, W., Avon, C., Dowling, T. C., Shao, C., Kane,
`M., Hoag, S. W., Flasar, M. H., Ting, T. Y., Polli, J. E. Reply to "On the Effect of Common
`Excipients on the Oral Absorption of Class 3 Drugs". J Pharm Sci 2016;105:1355-7.
`
`
`Papers Read at Scientific or Professional meetings (national/international; *trainee, presenter):
`
`
`1. Dowling, T. C., Shultz, C., Swanson, M., Bachmann, A.,"Probenecid Increases Renal Retention
`and Antitumor Activity of DFMO in Neuroblastoma," 2021 Translational Oncology Research
`Conference, Michigan State University, East Lansing, MI. (November 11, 2021).
`2. Cucci, M., Roberts, J., Murphy, C., Gerlach, A., Udy, A., Mangira, C., Dowling, T. C., Mullen, C.,
`2020 ACCP Spring Virtual Poster Symposium, "Performance of the Cockcroft-Gault equation
`using different body weights in ICU patients with augmented renal clearance: A preliminary
`analysis," American College of Clinical Pharmacy, Virtual. (May 27, 2020).
`3. *Swanson, M., Szarowicz, C., Dowling, T. C., Pike, S., Shultz, C., Bachmann, A., West Michigan
`Research Undergraduate Symposium (WMRUGS), "Development of an LCMS Assay to Quantify
`DFMO in Mouse Plasma," Van Andel Research Institute, Grand Rapids, MI. (November 4, 2019).
`4. *Swanson, M., Szarowicz, C., Dowling, T. C., Pike, S., Shultz, C., Bachmann, A., Society of
`
`
`
`8
`
`

`

`
`
`
`
`Toxicology, "Development of an LCMS Assay to Quantify DFMO in Mouse Plasma," Society of
`Toxicology, Ann Arbor, MI. (October 18, 2019).
`5. Stockton W, Nguyen T, Zhang L, Dowling T. 2018 ACCP Global Conference, "Etoposide
`hypersensitivity in pediatric patients," American College of Clinical Pharmacy, Seattle, WA.
`(October 22, 2018).
`6. Dowling TC, Reger M, Roff B, Durst SW, Robertson J, 2017 AACP Annual Meeting, "Student
`Pharmacist’s Competencies Achieved During a Pilot Co-Curricular Training Program in Precision-
`Based Behavioral Medicine," American Association of Colleges of Pharmacy, Nashville, TN. (July
`16, 2017).
`7. Dowling TC, Mindikoglu A, et al. 2017 AASLD Digestive Disease Week, "Robust Metabolomic
`Signature is Associated with Altered Renal Hemodynamics in Patients with Cirrhosis," AASLD,
`Chicago, IL. (May 7, 2017).
`8. Dowling TC, Mindikoglu A, et al. 2017 AASLD Digestive Disease Week, "Serum Creatinine in
`Female Patients with Cirrhosis Unfairly Bias Liver Transplant Wait List Ranking: Implications for
`Elimination of Gender Disparities in Access to Orthotopic Liver Transplantation," AASLD,
`Chicago, IL. (May 7, 2017).
`9. *Rungkitwattanakul, J., Dowling, TC. 2016 ACCP Annual Meeting, "Comparative review of
`tertiary medical sources on dialysis of drugs for patients receiving intermittent hemodialysis,"
`ACCP, Hollywood, FL. (October 23, 2016).
`10. Dorshow RB, Debreczeny M, Fink JC, Dowling TC. Initial Clinical Trial Results of a Real-Time
`Point-of-Care Glomerular Filtration Rate Measurement Utilizing a Novel Fluorescent Tracer
`Agent. Presented at the 2015 American Society of Nephrology Annual Scientific Meeting, San
`Diego, CA, Nov. 12, 2015.
`11. Seliger SL, Diggs CE, Dowling TC, Christenson R, Watnick TJ. Accuracy of Traditional and
`Novel Renal Filtration Markers for Estimating GFR in ADPKD Patients. Presented at the 2015
`American Society of Nephrology Annual Scientific Meeting, San Diego, CA, Nov. 14, 2015.
`12. Dorshow RB, Debreczeny MP, Dowling TC. Results of the First-in-Human Clinical Trial for MB-
`102, a Novel Fluorescent Tracer Agent for Real-Time Measurement of Glomerular Filtration Rate.
`Presented at the 2015 SPIE BiOs Expo, San Francisco, CA, Feb. 9, 2015.
`13. Seliger SL, Pham AT, Dowling TC, Diggs CE, Watnick TJ. Accuracy of creatinine-based
`estimating equations for GFR in ADPKD. Presented at the 2014 American Society of Nephrology
`Kidney Week® meeting, Philadelphia, PA, Nov. 15, 2014.
`14. *Hollis A, Heil E, Nicolau DP, Okondor P, Dowling TC, Thom K. Validation of a Dosing Strategy
`for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. Presented at the 2014 ACCP
`Annual Meeting, Austin, TX, Oct. 16, 2014.
`15. Heredia A, Medina-Moreno S, *Gao X, Le NM, Zapata JC, Reitz M, Bryant J, Dowling TC,
`Redfield RR. Inhibition of drug-resistant HIV by targeting cellular CDK9 in humanized mice.
`Presented at the 16th Annual International Meeting of the Institute of Human Virology, Baltimore,
`MD, Sept. 15, 2014.
`16. *Hollis A, Heil E, Nicolau DP, Okondor P, Dowling TC, Thom K. Validation of a Dosing Strategy
`for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. Presented at the 54th Interscience
`Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 6, 2014.
`17. Zhang S, Dowling TC. Review of web-based direct to consumer (DTC) resources for
`pharmacogenomics testing. Presented at the 2013 ASHP midyear meeting, Orlando, FL, Dec. 9,
`2013.
`18. Huang E, Spiegel A, Yang H, Wang H, Dowling TC. Renal n-acetyl-transferase activity and
`expression in HK-2 cells. Presented at the 2013 ACCP Annual meeting, Albuquerque, NM,
`October 16, 2013. Poster. Reviewed. Original Research.
`
`
`
`9
`
`

`

`
`
`
`
`19. Huang E, Chang Y, Lliang L, Dowling TC. Drug metabolism of PAH by NAT2 in human kidney
`(HK-2) cells. Presented at the 2012 ASHP midyear meeting, Las Vegas, NV, Dec. 4, 2012.
`20. Chang Y, Lliang L, Chan M, Dowling TC. Optimization of human kidney (HK-2) cell culture for
`OAT-mediated drug transport studies. Presented at the 2012 ASHP midyear meeting, Las Vegas,
`NV, Dec. 4, 2012.
`21. Matzke GR, Marks SA, Dowling TC, Murphy JE, Burckart GJ. Influence of Kidney Disease on
`Drug Pharmacokinetics: An Assessment of Industry Studies submitted to Food Drug
`Administration for New Molecular Entities 1999-2010. Presented at the American Society of
`Nephrology 2012 Annual Meeting, San Diego, CA, November 2, 2012.
`22. Volpe DA, Tobin GA, Tavakkoli F, Dowling TC, Parker RJ. Effect of Uremic Serum and Uremic
`Toxin on In Vitro Microsomal Metabolism. Presented at the 18th North American Regional ISSX
`Meeting, Dallas, TX, October 18, 2012.
`23. Agness C, Dowling TC, Hise M, Wang H, Li L. Influence of BSMI Vitamin D Receptor Gene
`Polymorphism on Response to Oral Vitamin D Therapy in Predialysis Patients American Journal
`of Kidney Diseases. Presented at the National Kidney Foundation 2012 Spring Clinical Meeting,
`Washington, DC, May 10, 2012.
`24. *Wang ES, Dowling TC. Comparison of Cockcroft-Gault (CG), Modification of Diet in Renal
`Disease (MDRD), and the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI)
`Equations for Renal Dose Adjustment in the Elderly. (Poster). Presented at the 2011 ASHP
`Midyear Meeting, December 6, 2011, New Orleans, LA.
`25. *Kitsul T, Dowling TC. Review of Renal Dosing Recommendations in FDA Product Labeling
`Information of Drugs Approved in 2006-2010.(Poster). Presented at the 2011 ASHP Midyear
`Meeting, December 6, 2011, New Orleans, LA.
`26. Dowling TC, Sorkin J, Ferrucci L. GFR Equations Overestimate Creatinine Clearance in Elderly
`Individuals Enrolled in the NIA-Baltimore Longitudinal Study on Aging (BLSA).(Invited, Podium)
`Great Eight Presentation at 2011 ACCP Annual Meeting, October 17, 2011, Pittsburgh, PA.
`27. Watson K, Gonzales J, Trovato JA, Dowling TC, Grover BE, Brandt NJ. Implementation of a
`structured residency/fellowship research development program. Presented at the 2011 ASHP
`Midyear Meeting, December 7, 2011, New Orleans, LA.
`28. Congdon HB, Dowling TC, Cheng I, Truong HA, Zarfeshan F. Evaluation of a Medication
`Therapy Management Program on Hemoglobin A1c Values in a Health Resources and Services
`Administration Patient Safety and Clinical Pharmacy Services Collaborative. (Poster). Presented
`at 2011 ACCP Annual Meeting, October 17, 2011, Pittsburgh, PA.
`29. Dowling TC, Allison S. Evaluation of renal function estimation methods to predict vancomycin
`pharmacokinetics. ACCP Annual Meeting, Oct. 19, 2010, Austin, TX.
`30. Dowling TC, Rodriguez de Bittner M, Perez Z, Briglia A, Peralta L. Pilot Evaluation of Renal
`Function in Hispanic Americans with Diabetes. 2010 ACCP Annual Meeting, Oct. 20, 2010,
`Austin, TX.
`31. *Jin R, Fossler MJ, Goldstein D, McHutchison JG, Howell CD, Dowling TC. Population
`Pharmacodynamic Model in Patients with Chronic Hepatitis C Virus Genotype 1. Presented at the
`2010 American College of Clinical Pharmacology Meeting, Baltimore, MD, September 13, 2010.
`32. Klein Schwartz W, Doyon S, Dowling T. Evaluation of a Novel Charcoal Cookie Formulation for
`Drug Adsorption. Presented at the 2010 ACCP Spring Research Meeting, Charlotte, NC, April
`2010.
`33. *Jin R, Fossler M, Dowling TC, Howell CD. Development of a Population Pharmacokinetic Model
`for Ribavirin. Presented at the 2009 American College of Clinical Pharmacology Meeting, San
`Antonio, TX, September 2009.
`
`
`
`10
`
`

`

`
`
`
`
`34. *Jin R, Fossler M, Dowling TC, Howell CD. Ribavirin Population Pharmacokinetics in African
`American and Caucasian American Patients Infected with Chronic Hepatitis C Genotype 1. 2009
`Digestive Disease Week, AASLD, Chicago, IL, June 2009.
`35. Dowling TC, Matzke GR, Murphy JE, Burckart GJ. Evaluation of renal dosing recommendations
`in FDA product labeling information of approved and marketed drugs. 2008 ACCP Annual
`Meeting, Louisville, KY, October 2008.
`36. *Rogers HL, Robinson S, Dowling TC, Liggett S, Gottlieb S. The role of Beta-1 adrenergic
`receptor SNPs in the treatment of heart failure with beta-blockers. 37th Annual Meeting of the
`American College of Clinical Pharmacology, Philadelphia, PA, September 2008. (*Student Award
`1st Prize Winner)
`37. *Jin R, Dowling TC, Howell CD. A Pharmacokinetic evaluation of ribavirin in African American
`and Caucasian patients with chronic hepatitis C. 37th Annual Meeting of the American College of
`Clinical Pharmacology, Philadelphia, PA, September 2008.
`38. *Rogers HL, Marshall J, Bock J, Dowling TC, Feller E, Robinson S, Gottlieb SS. A Randomized,
`Controlled Trail of the Renal Effects of Ultrafiltration as Compared to Furosemide. 11th Annual
`Scientific meeting of the Heart Failure Society of America, Washington, DC, September 16, 2007.
`39. *Kinjo M, *Iqbal T, Dowling TC. Relative Bioavailability of Ketoprofen 20% in PLO gel in Healthy
`Women. American Association of Pharmaceutical Scientists 2007 San Diego, CA, November
`2007.
`40. Jones-Burton C, *Vessal G, Dowling TC, Fink JC. Urinary cotinine as an objective measure of
`cigarette smoking in chronic kidney disease. Presented at the 39th Annual Meeting and Scientific
`Exposition of the American Society of Nephrology, San Diego, CA, November 15, 2006.
`41. Dittrich HC, Gupta DK, Hack TE, Dowling T, Tansey M, C